- Home
- RVP vs AKTX Comparison
RVP vs AKTX Comparison
Compare RVP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVP
- AKTX
- Stock Information
- Founded
- RVP 1994
- AKTX N/A
- Country
- RVP United States
- AKTX United States
- Employees
- RVP N/A
- AKTX N/A
- Industry
- RVP Medical/Dental Instruments
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RVP Health Care
- AKTX Health Care
- Exchange
- RVP Nasdaq
- AKTX Nasdaq
- Market Cap
- RVP 25.1M
- AKTX 26.5M
- IPO Year
- RVP 2001
- AKTX N/A
- Fundamental
- Price
- RVP $0.87
- AKTX $0.92
- Analyst Decision
- RVP
- AKTX Strong Buy
- Analyst Count
- RVP 0
- AKTX 2
- Target Price
- RVP N/A
- AKTX $3.30
- AVG Volume (30 Days)
- RVP 59.3K
- AKTX 462.2K
- Earning Date
- RVP 11-13-2025
- AKTX 11-18-2025
- Dividend Yield
- RVP N/A
- AKTX N/A
- EPS Growth
- RVP N/A
- AKTX N/A
- EPS
- RVP N/A
- AKTX N/A
- Revenue
- RVP $38,161,712.00
- AKTX N/A
- Revenue This Year
- RVP N/A
- AKTX N/A
- Revenue Next Year
- RVP N/A
- AKTX N/A
- P/E Ratio
- RVP N/A
- AKTX N/A
- Revenue Growth
- RVP N/A
- AKTX N/A
- 52 Week Low
- RVP $0.56
- AKTX $0.57
- 52 Week High
- RVP $0.89
- AKTX $3.70
- Technical
- Relative Strength Index (RSI)
- RVP 63.46
- AKTX 50.50
- Support Level
- RVP $0.80
- AKTX $0.74
- Resistance Level
- RVP $0.88
- AKTX $1.24
- Average True Range (ATR)
- RVP 0.03
- AKTX 0.13
- MACD
- RVP 0.00
- AKTX 0.01
- Stochastic Oscillator
- RVP 83.33
- AKTX 42.14
About RVP Retractable Technologies Inc.
Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The company's products are the VanishPoint 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the allergy tray; the IV safety catheter; the Patient Safe syringes; the Patient Safe Luer Cap; the VanishPoint Blood Collection Set; and the EasyPoint needle, as well as a standard 3mL syringe packaged with an EasyPoint needle. The company also sells VanishPoint autodisable syringes in the international market in addition to the Company's other products.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.